Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Solvvy, First Half Ordinary Profit Increases by 22%, Oct-Dec Ordinary Profit Increases by 77%
7320 Solvvy Inc. 【J-GAAP】
Earnings ReportSolvvy Inc. <7320> [TSE Growth] announced its financial results after the market closed on February 13th (15:31). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending June 2026 (July to December) increased 21.8% from the same period last year, reaching 1.04 billion yen. However, Progress toward the full-year plan of 2.50 billion yen was 41.8%, also falling below the five-year average of 49.3%.
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to June period (second half) is expected to expand 30.0% from the same period last year, reaching 1.45 billion yen.
In the most recent three-month period, from October to December (2Q), the consolidated ordinary profit increased 76.9% from the same period last year, reaching 0.66 billion yen. The operating profit margin rose from 18.1% in the same period last year to 20.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Dec, 2023 | 2,295 | 537 | 651 | 444 | 44.3 | 43.1 | Feb 9, 2024 | J-GAAP |
| Jul - Dec, 2024 | 2,980 | 668 | 857 | 300 | 28.6 | 43.3 | Feb 13, 2025 | J-GAAP |
| Jul - Dec, 2025 | 3,276 | 557 | 1,044 | 698 | 60.9 | 41.8 | Feb 13, 2026 | J-GAAP |
| YoY | +9.9% | -16.6% | +21.8% | +132.7% | +113.2% |
First Half Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Dec, 2025 Guidance | 3,600 | 810 | 1,040 | 695 | 61.7 | 10 | Aug 13, 2025 | J-GAAP |
| Jul - Dec, 2025 Results | 3,276 | 557 | 1,044 | 698 | 60.9 | 10 | Feb 13, 2026 | J-GAAP |
| Revision Rate | -9.0% | -31.2% | +0.4% | +0.4% | -1.2% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 3,725 | 952 | 1,120 | -928 | -84.2 | 14 | Aug 13, 2025 | J-GAAP |
| Jan - Jun, 2026 Guidance | 4,924 | 1,543 | 1,456 | 927 | 82.3 | 10 | Feb 13, 2026 | J-GAAP |
| YoY | +32.2% | +62.1% | +30.0% | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jun, 2024 | 5,359 | 1,240 | 1,512 | 973 | 96.9 | 7.50 | Aug 9, 2024 | J-GAAP |
| Jun, 2025 | 6,705 | 1,620 | 1,977 | -628 | -57.0 | 14 | Aug 13, 2025 | J-GAAP |
| Jun, 2026 Guidance | 8,200 | 2,100 | 2,500 | 1,625 | 144.2 | 20 | Aug 13, 2025 | J-GAAP |
| YoY | +22.3% | +29.6% | +26.5% | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 1,507 | 273 | 377 | -26 | -2.5 | 18.1 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,679 | 379 | 503 | -25 | -2.3 | 22.6 | May 13, 2025 | J-GAAP |
| Apr - Jun, 2025 | 2,046 | 573 | 617 | -903 | -81.9 | 28.0 | Aug 13, 2025 | J-GAAP |
| Jul - Sep, 2025 | 1,534 | 201 | 377 | 247 | 21.5 | 13.1 | Nov 12, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,742 | 356 | 667 | 451 | 39.4 | 20.4 | Feb 13, 2026 | J-GAAP |
| YoY | +15.6% | +30.4% | +76.9% | - | - |
Related Articles
BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens
VELTRA, 3.7 times Increase in Ordinary Profit for The Current Fiscal Year
Dynamic Map, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Widens, Oct-Dec Ordinary Profit Loss Widens
LIFE CREATE, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 41% Decrease
Asia Air Survey, Oct-Dec (1Q) Operating Profit Turns to Profit
OPTIMUS GROUP, Undisclosed Pretax Income to Reach 5.9 Billion Yen for The Current Fiscal Year
STI Foods Holdings, Last Fiscal Year's Ordinary Profit Unexpectedly Declines, 0.04% Decrease in The Current Fiscal Year
eWeLL, 25% Increase in Ordinary Profit, Update Record High for Seventh Consecutive Term, Dividend Raised by 5 Yen
MINKABU THE INFONOID, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Profit, Exceeds Full-Year Plan
POLA ORBIS, Last Fiscal Year's Ordinary Profit Unexpectedly Increases, 2% Increase in The Current Fiscal Year